Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Adjuvant and Neoadjuvant HER2 Therapy
Introduction HER2 (also known as ERBB2) represents a potent oncogenic driver in 15% to 20% of breast carcinomas and is associated with an aggressive phenotype and poor patient outcome if not treated. The addition of trastuzumab, the first monoclonal antibody…